Literature DB >> 31609157

CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers.

Charles Brown1, Farzad Sekhavati2, Ruben Cardenes2, Claudia Windmueller2, Karma Dacosta1, Jaime Rodriguez-Canales1, Keith E Steele1.   

Abstract

There is an important need in immuno-oncology to develop reliable immunohistochemistry (IHC) to assess the expression of CTLA-4+ tumor-infiltrating lymphocytes in human cancers and quantify them with image analysis (IA). We used commercial polyclonal and monoclonal antibodies and characterized three chromogenic cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) assays with suitable specificity and sensitivity for use in formalin-fixed, paraffin-embedded (FFPE) tissues. We found variable numbers of CTLA-4+ lymphocytes in multiple types of cancer and secondary lymphoid organs (SLOs) and other normal human tissues. Combining CTLA-4 with CD3, CD4, or CD8 by immunofluorescence showed that CTLA-4+ lymphocytes in SLOs and tumors were typically CD3+ and CD4+, but not CD8+. Individual lymphocytes expressed CTLA-4 either as primarily granular cytoplasmic staining or as excentric globular deposits. The CTLA-4/FoxP3 (forkhead box P3 protein) duplex IHC demonstrated that CTLA-4+/FoxP3- lymphocytes predominated in the germinal centers of SLOs and tumor tertiary lymphoid structures (TLSs), whereas CTLA-4+/FoxP3+ lymphocytes populated the T-cell zone of SLOs and TLSs, plus tumor stroma. IA scoring was highly comparable with pathologist scoring for CTLA-4 and CTLA-4/FoxP3 assays and a FoxP3 single IHC. Our findings show that CTLA-4 IHC can be used to reliably label lymphocytes in FFPE human tissues, making it possible to investigate the role of CTLA-4 in the tumor microenvironment.

Entities:  

Keywords:  CTLA-4; FoxP3; cancer; image analysis; immuno-oncology; immunohistochemistry

Year:  2019        PMID: 31609157      PMCID: PMC6882065          DOI: 10.1369/0022155419882292

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  36 in total

Review 1.  Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters.

Authors:  Takashi Saito; Tadashi Yokosuka; Akiko Hashimoto-Tane
Journal:  FEBS Lett       Date:  2010-11-24       Impact factor: 4.124

2.  A proposal for validation of antibodies.

Authors:  Mathias Uhlen; Anita Bandrowski; Steven Carr; Aled Edwards; Jan Ellenberg; Emma Lundberg; David L Rimm; Henry Rodriguez; Tara Hiltke; Michael Snyder; Tadashi Yamamoto
Journal:  Nat Methods       Date:  2016-09-05       Impact factor: 28.547

3.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

Review 4.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

5.  Controls for immunohistochemistry: the Histochemical Society's standards of practice for validation of immunohistochemical assays.

Authors:  Stephen M Hewitt; Denis G Baskin; Charles W Frevert; William L Stahl; Eduardo Rosa-Molinar
Journal:  J Histochem Cytochem       Date:  2014-07-14       Impact factor: 2.479

6.  Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.

Authors:  D V Chan; H M Gibson; B M Aufiero; A J Wilson; M S Hafner; Q-S Mi; H K Wong
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

7.  Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Authors:  Edwin R Parra; Pamela Villalobos; Carmen Behrens; Mei Jiang; Apar Pataer; Stephen G Swisher; William N William; Jiexin Zhang; Jack Lee; Tina Cascone; John V Heymach; Marie-Andrée Forget; Cara Haymaker; Chantale Bernatchez; Neda Kalhor; Annikka Weissferdt; Cesar Moran; Jianjun Zhang; Ara Vaporciyan; Don L Gibbons; Boris Sepesi; Ignacio I Wistuba
Journal:  J Immunother Cancer       Date:  2018-06-06       Impact factor: 13.751

Review 8.  Treg and CTLA-4: two intertwining pathways to immune tolerance.

Authors:  Lucy S K Walker
Journal:  J Autoimmun       Date:  2013-07-10       Impact factor: 7.094

9.  OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.

Authors:  Ryan Montler; R Bryan Bell; Colin Thalhofer; Rom Leidner; Zipei Feng; Bernard A Fox; Allen C Cheng; Tuan G Bui; Christopher Tucker; Helena Hoen; Andrew Weinberg
Journal:  Clin Transl Immunology       Date:  2016-04-15

10.  Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Authors:  Fei Tang; Xuexiang Du; Mingyue Liu; Pan Zheng; Yang Liu
Journal:  Cell Biosci       Date:  2018-04-18       Impact factor: 7.133

View more
  5 in total

1.  Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.

Authors:  Grazia Graziani; Lucia Lisi; Lucio Tentori; Pierluigi Navarra
Journal:  Exp Suppl       Date:  2022

2.  Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.

Authors:  Jiannong Li; Inna Smalley; Zhihua Chen; Jheng-Yu Wu; Manali S Phadke; Jamie K Teer; Thanh Nguyen; Florian A Karreth; John M Koomen; Amod A Sarnaik; Jonathan S Zager; Nikhil I Khushalani; Ahmad A Tarhini; Vernon K Sondak; Paulo C Rodriguez; Jane L Messina; Y Ann Chen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

Review 3.  The Use of Quantitative Digital Pathology to Measure Proteoglycan and Glycosaminoglycan Expression and Accumulation in Healthy and Diseased Tissues.

Authors:  A Sally Davis; Mary Y Chang; Jourdan E Brune; Teal S Hallstrand; Brian Johnson; Sarah Lindhartsen; Stephen M Hewitt; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2020-09-16       Impact factor: 2.479

4.  Identification of CTLA-4-Positive Cells in the Human Tonsil.

Authors:  Markus Tiemann; Dmitri Atiakshin; Vera Samoilova; Igor Buchwalow
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

5.  Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.

Authors:  Alireza Samiei; David W Gjertson; Sanaz Memarzadeh; Gottfried E Konecny; Neda A Moatamed
Journal:  Diagn Pathol       Date:  2022-09-14       Impact factor: 3.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.